kabutan

Veritas In Silico Inc.(130A) Summary

130A
TSE Growth
Veritas In Silico Inc.
503
JPY
-7
(-1.37%)
Dec 5, 12:30 pm JST
3.24
USD
Dec 4, 10:30 pm EST
Result
PTS
outside of trading hours
507.8
Dec 5, 10:13 am JST
Summary Chart Historical News Financial Result
PER
PBR
1.70
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
508 JPY 3.27 USD
Previous Close Dec 4
510 JPY 3.28 USD
High Dec 5, 9:00 am
508 JPY 3.27 USD
Low Dec 5, 9:09 am
500 JPY 3.22 USD
Volume
6,900
Trading Value
3.00M JPY 0.02M USD
VWAP
505.33 JPY 3.26 USD
Minimum Trading Value
50,300 JPY 324 USD
Market Cap
3.26B JPY 0.02B USD
Number of Trades
34
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
332
1-Year High Jul 31, 2025
10,270
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 337,100
Nov 21, 2025 0 340,900
Nov 14, 2025 0 347,700
Nov 7, 2025 0 387,800
Oct 31, 2025 0 397,000
Company Profile
Veritas In Silico operates a platform business for small molecule and nucleic acid drug discovery targeting mRNA.
Sector
Pharmaceuticals
Veritas In Silico Inc. is a Japan-based bio-pharmaceutical company. The company develops a platform for small molecule and nucleic acid drug discovery, specializing in targeting mRNA. It focuses on diseases that cannot be addressed by conventional protein-targeted drug discovery approaches. Using their proprietary in silico RNA structure analysis technology, Veritas In Silico has realized a drug discovery approach that targets partial structures on mRNA. This enables the creation of pharmaceuticals that address unmet medical needs. The company collaborates with multiple pharmaceutical companies, promoting joint research based on their drug discovery platform "ibVIS". By targeting mRNA, Veritas In Silico aims to open up new possibilities in the field of drug discovery and development.